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Abstract
To estimate the prevalence of metabolic syndrome (MS) in a population receiving attention in primary care centers
(PCC) we selected a random cohort of ostensibly normal subjects from the registers of 5 basic-health area (BHA) PCC.
Diagnosis of MS was with the WHO, NCEP and IDF criteria. Variables recorded were: socio-demographic data, CVD
risk factors including lipids, obesity, diabetes, blood pressure and smoking habit and a glucose tolerance test outcome.
Of the 720 individuals selected (age 60.3 ± 11.5 years), 431 were female, 352 hypertensive, 142 diabetic, 233 pre-diabetic,
285 obese, 209 dyslipemic and 106 smokers. CVD risk according to the Framingham and REGICOR calculation was 13.8
± 10% and 8.8 ± 9.8%, respectively. Using the WHO, NCEP and IDF criteria, MS was diagnosed in 166, 210 and 252
subjects, respectively and the relative risk of CVD complications in MS subjects was 2.56. Logistic regression analysis
indicated that the MS components (WHO set), the MS components (IDF set) and the female gender had an increased
odds ratio for CVD of 3.48 (95CI%: 2.26–5.37), 2.28 (95%CI: 1.84–4.90) and 2.26 (95%CI: 1.48–3.47), respectively. We
conclude that MS and concomitant CVD risk is high in ostensibly normal population attending primary care clinics, and
this would necessarily impinge on resource allocation in primary care.
Published: 22 July 2008
BMC Public Health 2008, 8:251 doi:10.1186/1471-2458-8-251
Received: 15 January 2008
Accepted: 22 July 2008
This article is available from: http://www.biomedcentral.com/1471-2458/8/251
© 2008 Cabré et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
Page 2 of 12
(page number not for citation purposes)
Background
The metabolic syndrome (MS) was first described in 1998
by Reaven as "syndrome X". Although previously alluded-
to by several authors (Kylin, Marañón and others) and
termed a multi-metabolic syndrome or insulin resistance,
it represented a known risk factor in the development of
cardiovascular disease events and was associated with
accelerated atherosclerosis [1].
From the classical description by Reaven [2], a common
nexus was established: insulin resistance/hyperinsuline-
mia. Surprisingly, this author did not include obesity in
the definition. Later, other authors included the concept
of alterations in fat, disorders of glucose, dyslipemias and
hypertension. Recently, a growing interest has developed
and MS has been receiving attention not only in hospital-
based medicine but also in primary care (PC); albeit in the
latter case the number of studies has been considerably
lower. Since epidemiological studies suggest that > 25% of
the general population will gradually develop insulin
resistance [3] it would appear that this pathology will be
diagnosed and treated increasingly within the ambit of PC
[4-6] and, as such, has become included in the list of pri-
orities of various public health-care authorities.
Apart from the difficulty in identifying its components,
there is the added the lack of consensus diagnostic criteria.
The initial criteria were those of the WHO in 1998 [7] and
subsequently those of the NCEP-ATP III in 2001 which
identified clinical types and simplified their management
[8]. Other criteria of note are those of EGIR (European
Group for the study of Insulin Resistance) based on Euro-
pean populations and were the first that defined preva-
lences in and around Spain. Subsequently, the American
Association of Clinical Endocrinologists (AACE) devel-
oped their criteria in 2003 and, finally, the International
Diabetes Federation (IDF) in 2005 issued its consensus
document [9]. Irrespective of the criteria used, the cer-
tainty is that MS is very prevalent [10-12] and the initial
studies in the USA recognize MS as a principal problem of
health with developed countries, and with elevated social
and economic consequences.
Reaven recognized some features frequently associated
with MS (syndrome of polycystic ovaries, endothelial
alteration and non-alcoholic hepatic steatosis)[13]. Of
note is that the very existence of MS as a disease entity has
been placed in doubt [14] such that the American Diabe-
tes Association (ADA) and the European Association for
the Study of Diabetes (EASD) recommended that patients
are not to be labeled as MS. However, the IDF has pub-
lished new criteria for MS adapted to different ethnic
groups, among which is the European population [15].
The relationship between MS and cardiovascular disease
has been well documented in the biomedical literature
[16-21].
References in PC in Spain are available [22-28], and seems
to highlight a high-risk population in our country, i.e.
hypertension of 47.8% in some samples. In another inves-
tigation, the prevalence of MS was calculated as 50.6%
overall in patients who had hypertension, dyslipemia,
diabetes or a combination of these 3 elements.
As such, MS constitutes a multi-pathology frequently
encountered in PC consulting rooms and its high preva-
lence would indicate the need for alertness in identifying
the syndrome and to treatment its components in order to
minimize the risk of subsequent cardiovascular disease.
Objectives
1) To determine the prevalence of MS in the population
receiving attention in PC.
2) To indentify factors or components of MS that inde-
pendently influence the cardiovascular disease prognosis
related to MS.
3) To analyse the impact of each component on the
appearance of cardiovascular disease events.
Methods
a) Design
Prospective, multi-centered cohort study to observe the
appearance of cardiovascular disease events. There were 2
cohorts: patients with the diagnosis of MS and those sub-
jects without MS. Follow-up was for 2 years.
b) Study population
Patients who were attending 5 Basic Health-care Areas
(BHA) in Catalonia, Spain; 4 in the urban city of Reus and
the 5th located in the rural area of Deltebre. The catchment
area of the PC centers has a total of approximately 72,000
individuals. The selection for the present study was
patients of both genders aged above 45 years, and who
had attended the clinical center at least once in the previ-
ous 3 years.
Using the Computerized System for Patient Care (CSPC)
we selected a random list of individuals to reflect the dis-
tributions of the total of those subjects registered and
assigned by the Governmental Health-service Authority to
the different PC centers. Under the National Health Serv-
ice provisions in Catalonia, all citizens are entitled to free-
at-the-point-of-access medical attention which, under
most circumstances, is the local PC center. The selected
subjects were contacted and informed of the study and
their written consent to participation was solicited. TheBMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
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objectives of the study were explained and, as an induce-
ment, a thorough medical check-up and follow-up was
offered. The tests included blood constituent analyses and
a 75 g glucose tolerance test (except for known diabetics).
All the blood samples were analyzed in the same hospital
clinical laboratory which has international quality stand-
ard ceditation (ISO9002). Standard clinical history was
taken and included information on pharmacological and
non-pharmacological drugs used, advice on tobacco habit
and on diet, and information with respect to MS diagnosis
as well as any other possible illnesses. The exclusion crite-
rion was that of having suffered any cardiovascular disease
complication prior to recruitment to the present study.
This item was evaluated from the clinical notes by 2 differ-
ent members of the investigation team and, in case, of
non-concordance, the opinion of a 3rd  member was
sought.
c) Study period
From 30th June 2004 to 30th June 2006.
d) Information sources
We designed multi-parameter data collection forms on
which the clinical history data were recorded at the initial
interview as well as from the archived data recorded at
each of the participating BHA centers. The items included;
date of registration at the center, family and personal his-
tory, cardiovascular disease risk factors (hypertension,
diabetes mellitus, dyslipemia, obesity), dietary and/or
pharmacological treatments, blood constituent measure-
ments, presence of vascular complications. The cardiovas-
cular risk was calculated according to the 2 methods; the
Framingham equation [29], and the REGICOR formula
[30] (a calibration of Framingham algorhitm adapted for
Spain) for each individual participant.
e) Definition of variables
Age, gender, weight, height, body mass index (BMI), con-
centrations of plasma triglycerides, total cholesterol,
HDL-cholesterol, LDL-cholesterol, uric acid, baseline
insulinemia, baseline glycemia, glycemia at 2 h post-glu-
cose load, fibrinogen, leukocyte count, glycated hemo-
globin, waist-hip ratio, abdominal circumference, blood
pressure, family history of cardiovascular disease and of
diabetes, smoking habit, alcohol consumption, dietary
and/or pharmacological treatment, presence of vascular
complication as well as the date when these complica-
tions had been diagnosed.
f) Definition of MS criteria and cardiovascular diseases
The criteria defining MS according to the NCEP-ATPIII
require a combination of at least 3 of the 5 following cri-
teria:
- Abdominal circumference ≥ 102 cm in males or ≥ 88 cm
in females.
- HDL cholesterol < 1.03 mmol/mL (< 40 mg/dL) [males]
or < 1.3 mmol/mL (< 50 mg/dL) [females].
- Triglycerides ≥ 1.7 mmol/mL (≥ 150 mg/dL).
- Blood pressure ≥ 130/85 mmHg or the patient receiving
hypotensive treatment.
- Baseline glycemia > 6.1 mmol/mL (> 110 mg/dL).
Additionally, IDF criteria are the same precedent with the
only differences of:
a) Abdominal circumference is, for European people, ≥ 94
cm in males or ≥ 80 cm in females.
b) Fasting glycemia > 5.55 mmol/l (> 100 mg/dL).
According to the WHO criteria, an individual is consid-
ered to have MS if:
- Glucose intolerance/diabetes/IFG and/or insulin resist-
ance (determined with functional laboratory tests) plus:
- Two or more of the following criteria:
￿ Hypertension (or its treatment).
￿ Hypertriglyceridemia of > 1.7 mmol/mL (> 150 mg/dL)
or LDL < 0.9 mmol/mL (< 35 mg/dL) [males] and < 1.0
mmol/mL (< 39 mg/dL) [females].
￿ BMI > 30 or WHI (waist-hip index) > 0.9 [males] or >
0.85 [females].
￿ Microalbuminuria (> 20 μg/min) or urinary albu-
min:creatinine ratio > 30 mg/g.
The patients who fulfilled the NCEP criteria for MS were
entered into the study under as the MS cohort. The cohort
defined as non-MS was composed of those patients that
did not fulfill the NCEP criteria.
Cardiovascular disease complications were defined as
ICD-9 codes corresponding to:
- Coronary heart disease: clinical history of ischemic heart
disease (myocardial infarction, angina) and/or cardiac
insufficiency, complementary assessments (ECG, stress
test, scans...) (Codes 411 to 416).BMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
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- Cerebrovascular disease; clinical history suggestive of
transitory ischemic attack/cerebrovascular accident and/
or image tests that show such evidence (Codes 430 to
438).
- Peripheral vascular disease: intermittent claudication,
absence of peripheral pulse or demonstrated by Doppler
(ankle-brachial index < 0.9). (Codes 250.7, 443).
- Diabetic retinopathy: findings in the fundus of the eye
compatible with the disease (Code 362).
- Nephropathy: microalbuminuria > 30 mg/24 h.
- Diabetic neuropathy: employing the Diabetic Neuropa-
thy Symptom (DNS) scale that varies between 0–4 points,
with neuropathy defined as a score of ≥ 1 point. Further
corroboration with a pathology assessment using 10G-
Semmes-Weinstein monofilament in one of more of the 6
plane areas evaluated.
- Also considered as a complication are those deaths
related to cardiovascular disease e.g. myocardial infarc-
tion that causes death.
g) Determination of sample size
With an α risk of 0.05 for a precision of ± 3% in a two-
tailed test of difference in proportions of MS estimated as
17%, the requirement for a random population sample
was 738 subjects; assuming the target population to be
36,600 individuals (36.6% of the total population
defined). The loss rate was estimated at 20% (Programa
Granmo version 5.2, Institut Municipal d'Investigació Mèdica
de Barcelona) [31].
h) Program of analysis
Epidemiological assessment: Possible associations
between different variables or components of MS, with an
increase in risk of having cardiovascular disease pathol-
ogy.
Statistical analyses: the data obtained were analyzed using
SPSS program (version 12.0) working with a confidence
level of 95% and considering differences as being statisti-
cally significant at p < 0.05. Initially, a descriptive analysis
was performed of the variables, and subsequent stepwise
multivariate analyses were performed in order to deter-
mine the relative importance of the different risk factors as
cause of the cardiovascular event. In the multivariate anal-
yses, the dependent variable was the number of events
and the independent variables were the dichotomized risk
factors (hypertension, dyslipemia, diabetes, obesity). Also
included was the dichotomized (presence/absence) varia-
ble of MS diagnosed on the WHO, NCEP and IDF criteria.
The results are presented adjusted for age and gender, with
respect to the variables that were significant in the model
as well as the coefficients or the b-exponential that explain
the percentage prediction of each variable considered in
the analyses.
Results
Of the 750 subjects selected, 30 were excluded due to hav-
ing had previous cardiovascular disease events. Of the 720
subjects followed-up, there were 29 (4%) losses: 8 cardio-
vascular disease deaths, 7 deaths from non-cardiovascular
disease, 7 had moved out of the local area and 7 were lost
to follow-up. Figure 1 describes flow of the study.
The overall mean age was 60.3 ± 11.5 years and 431 were
female (59.9%). The risk factors were: hypertension in
352 (48.9%), diabetes type 2 in 142 (19.7%), pre-diabe-
tes in 233 (32.4%), obesity in 285 (39.6%), dyslipemia in
209 (29%), and 106 (14.7%) were smokers. The mean
BMI was 29.1 ± 5.2 kg/m2. The mean cardiovascular risk
index (according to the Framingham score) was 13.8 ±
10% and, according to the REGICOR tables, was 8.8 ±
9.8%; both projected to 10 years.
With respect to MS, the study detected 166 subjects
(23.1%; 95%CI: 20.0–26.3) who fulfilled the MS diagnos-
tic criteria according to the WHO, and 210 (29.2%,
95%CI: 26.9–32.6) according to the NCEP-ATPIII criteria;
141 individuals fulfilled both definitions. 252 subjects
(35.0%; 95%CI: 31.5–38.6) fulfilled IDF criteria; of them
210 fulfilled the NCEP criteria too. The kappa (κ) index of
concordance between the first two sets of criteria defining
MS was 0.66 (p < 0.001) and between the second two sets
was 0.87 (p < 0.001).
Table 1 summarizes the information on the principal
characteristics of the study sample segregated into two
groups; without MS according to the NCEP criteria and
those with MS according to the same criteria.
Cardiovascular disease complications appeared in 113
(15.7%) subjects during the follow-up of 2 years. Overall,
there were 142 different complications: 35 (4.9%) were
peripheral vascular disease, 30 (4.2) coronary artery dis-
ease, 29 (45) nephrotic syndrome, 24 (3.3%) cerebrovas-
cular disease, 18 (2.5%) classified as having retinopathy
and 6 (0.8%) developed neuropathy. Segregated by
cohort, the group with MS suffered 15 coronary complica-
tions, 12 cerebrovascular, 18 peripheral artery disease, 11
retinopathies, 25 nephropathies and 5 neuropathies.
Conversely, in the group without MS, the complications
were 15 coronary disease, 12 cerebrovascular, 17 periph-
eral vascular disease, 7 retinopathies, 4 nephropathies and
1 neuropathy.BMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
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Flow chart of the study: Prospective, multi-centered cohort study to evaluate the cardiovascular disease event associated with  metabolic syndrome in a randomly selected study sample Figure 1
Flow chart of the study: Prospective, multi-centered cohort study to evaluate the cardiovascular disease event associated 
with metabolic syndrome in a randomly selected study sample.
Study population 
98,657 in the catchement area of Reus and 
Deltebre (Catalonia) 
Random sample 
General population >45 years assigned to the 
Primary Care centres by the NHS 
750 subjects 
Excluded 
Clinical history of CVD;n=30 
Population study sample 
720 subjects 
29 lost to follow-up 
8 deaths from CVD 
7 non-CVD deaths 
7 moved from area 
 7 not known 
Cohort with MS 
(NCEP criteria): 
210 individuals 
18 lost to follow-up: 
4 deaths from CVD  
5 non-CVD deaths 
4 moved from area  
5 not known 
11 lost to follow-up:  
4 deaths from CVD 
2 non-CVD deaths 
 3 moved from area 
2 not known 
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Table 1: Clinical and metabolic characteristics of the subjects as a function of the diagnosis of MS based on the NCEP-ATPIII criteria
TOTAL (n = 720) Metabolic Syndrome (NCEP) P
No (n = 510) Yes (n = 210)
Females 60.6(436) 51.4(262) 82.8(174) < 0.001
Age;years 66.9(SD = 10.9) 63.2(SD = 11.2) 70.6(SD = 9.3) < 0.001
Obesity 39.6(285) 22.3(114) 81.4(171) < 0.001
BMI(kg/m2) 29.1(SD = 5.2) 27.7(SD = 4.6) 32.1(SD = 5.2) < 0.001
FEMALES 27.9(SD = 6.0) 27.5(SD = 5.4) 33.5(SD = 4.9) < 0.001
MALES 27.7(SD = 4.7) 27.1(SD = 3.9) 28.7(SD = 5.3) < 0.001
Abdominal circumference(cm) 100.7(SD = 11.7) 95.8(SD = 13.0) 107.2(SD = 13.8) < 0.03
Blood pressure 48.9(352) 36.1(184) 80.0(168) < 0.001
BPS(mmHg) 132.0(SD = 17.6) 130.3(SD = 19.4) 142.0(SD = 18.7) < 0.001
FEMALES 131.6(SD = 20.7) 127.4(SD = 19.3) 140.4(SD = 17.8) < 0.001
MALES 133.4(SD = 18.1) 129.1(SD = 16.3) 145.6(SD = 18.7) < 0.001
BPD(mmHg) 78.1(SD = 11.6) 78.4(SD = 11.7) 82.4(SD = 11.1) < 0.001
FEMALES 78.5(SD = 11.7) 76.4(SD = 11.1) 81.6(SD = 10.5) < 0.001
MALES 79.6(SD = 11.6) 79.0(SD = 11.0) 83.7(SD = 11.6) < 0.001
Diabetes mellitus 19.7(142) 8.8(45) 60.5(127) < 0.001
Baseline glycemia(mg/dL) 106.7(SD = 38.7) 102.1(SD = 31.7) 127.4(SD = 55.8) < 0.001
FEMALES 111.4(SD = 42.3) 97.3 (SD = 27.5) 139.4(SD = 51.8) < 0.001
 MALES 114.8(SD = 46.0) 103.6(SD = 41.0) 133.5(SD = 48.1) < 0.001
HbA1c;% 5.6(SD = 1.5) 5.4(SD = 1.3) 6.2(SD = 2.0) < 0.001
FEMALES 6.04 (SD = 1.8) 5.32(SD = 1.2) 6.7(SD = 2.0) < 0.001
 MALES 6.11(SD = 1.9) 6.03(SD = 2.1) 6.2(SD = 1.6) < 0.001
Dyslipemia 29.0(209) 16.1(82) 60.5(127) < 0.001
Total cholesterol(mg/dL) 219.2(SD = 40.1) 217.3(SD = 42.5) 226.6(SD = 46.3) < 0.01
FEMALES 219.6(SD = 41.5) 215.4(SD = 44.2) 239.7(SD = 52.6) < 0.001
MALES 218.5(SD = 43.9) 217.9(SD = 43.9) 223.5(SD = 42.8) < 0.01
LDL-cholesterol(mg/dL) 141.3(SD = 36.3) 140.9(SD = 35.9) 143.2(SD = 36.7) NS
FEMALES 141.2(SD = 36.1) 139.8(SD = 36.3) 141.7(SD = 36.5) NS
MALES 145.2(SD = 37.2) 143.3(SD = 35.8) 147.2(SD = 39.4) NS
HDL-cholesterol(mg/dL) 54.4(SD = 19.0) 54.0(SD = 16.6) 50.8(SD = 17.4) < 0.001
FEMALES 53.2(SD = 18.2) 58.7(SD = 18.4) 52.4(SD = 16.1) < 0.001
MALES 50.9(SD = 22.3) 52.2(SD = 20.6) 50.1(SD = 20.8) NS
Triglycerides(mg/dL) 151.4(SD = 109.6) 147.0(SD = 107.0) 165.4(SD = 118.3) < 0.001
FEMALES 134.0(SD = 79.2) 104.4(SD = 59.2) 177.5(SD = 87.1) < 0.001
MALES 174.0(SD = 135.7) 148.0 (SD = 123) 210.5(SD = 146.2) < 0.002
Microalbuminuria(mg/d) 38.3(SD = 131.2) 18.2(SD = 64.1) 103.8(SD = 233) < 0.002
FEMALES 17.8(SD = 42.3) 13.7(SD = 18.2) 24.5(SD = 64.1) < 0.001
MALES 65.5(SD = 191.3) 42.5(SD = 112.4) 101.7(SD = 269) < 0.001
CVD risk(% at 10 years) 13.8(SD = 10.0) 13.4(SD = 8.3) 23.8(SD = 10.0) < 0.001
FEMALES 8.7(SD = 7.9) 6.5(SD = 5.3) 17.3(SD = 10.0) < 0.001
MALES 19.7(SD = 11.1) 14.4(SD = 9.8) 26.4(SD = 11.6) < 0,001
REGICOR(% at 10 years) 8.8(SD = 9.8) 7.2(SD = 8.9) 10.7(SD = 9.5) < 0.001
FEMALES 3.7(SD = 5.3) 2.9(SD= 4.7) 5.6(SD = 7.1) < 0.001
 MALES 10.1(SD = 8.8) 8.2(SD = 9.0) 13.5(SD = 9.4) < 0.001
CVD complications 19.7(142) 113 individuals 11.0(56) 55 individuals 40.9(86) 58 individuals < 0.001
Cerebrovascular 3.3(24) 2.3(12) 5.7(12) < 0.001
Coronary 4.2(30) 2.9(15) 7.1(15) < 0.001
Peripheral vascular 4.9(35) 3.3(17) 8.6(18) < 0.001
Retinopathy 2.5(18) 1.4(7) 5.2(11) < 0.02
Nephropathy 4.0(29) 0.8(4) 11.9(25) < 0.001
Neuropathy 0.8(6) 0.2(1) 2.4(5) < 0.001
The data are expressed in percentages (absolute values) and mean (SD:standard deviation). BPS = systolic blood pressure; BPD = diastolic blood 
pressure; BMI = body mass index; CVD = cardiovascular disease risk according to the Framingham predictive equation; REGICOR: cardiovascular 
disease risk tables based on the Framingham equations and calibrated for Spain; NS = not significantBMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
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Forward stepwise multiple logistic regression analyses of
the factors that influenced the appearance of the cardio-
vascular disease events are summarized in Table 2 and
from which it is of note that each MS classification carries
a different weight for different complications. As observed
in the multivariate analyses (Table 2) the WHO criteria are
better predictive of cardiovascular disease event than
those of the IDF. This is evident when the complications
are considered globally (OR = 3.48) as well as individually
(i.e. cases of coronary artery disease, vascular disease and
nephropathy). Conversely, the NCEP criteria predict the
cerebrovascular, arteriopathy, nephropathy and neuropa-
thy complication. IDF criteria predict the globally compli-
cations, as well as coronary, retinopathy and
nephropathy.
The  χ2 analysis of the number of components of MS
(NCEP criteria) indicated significant differences (p <
0.001) between the subjects with 0, 1 or 2 components
(absence of MS) and those that had 3, 4 or 5 (presence of
MS). The prevalence of events was 10.78% in subjects free
of MS and 27.61% in subjects suffering from MS (OR =
2.56).
The differences were, as well, significant with the χ2 test (p
< 0.001) between individuals who did, and did not, fulfill
the criteria using the WHO criteria. The prevalence of CVD
events was 10.8% in the group without MS and 31.9% in
the group with MS (OR = 2.95).
The rate of cardiovascular disease events during the first 2
years of follow-up was 98.6 events/1,000 patient-years.
In Figure 2 describes the increasing number of events per
1,000 inhabitants/year segregated with respect to the
number of MS components (NCEP criteria).
Figure 3 depicts the progressively increasing numbers of
events in relation to the number of MS components
(WHO criteria).
Figure 4 describes the number of events in relation to the
number of MS components (IDF criteria).
In a sub-analysis of the patients without diabetes (n =
578) we observed that 93 had NCEP criteria for MS and,
by the end of the follow-up period, these cases developed
16 (17.2%) complications. Conversely, in the subgroup
of 485 subjects without MS or diabetes, there were a total
of 43 (8.9%) cardiovascular disease complications.
Considering the diabetic patients alone (n = 142), 97 ful-
filled the NCEP criteria for MS and, at 2 years of follow-
up, there were 62 (63.9%) CVD complications compared
to 21 in the 45 (46.6%) diabetic individuals without MS.
Discussion
In primary care, the prevalence observed of MS is high and
close to the values described in the worldwide literature,
Table 2: Logistic regression of component factors in cardiovascular disease risk, adjusted for age and gender.
CVD complication B exponential = Odds Ratio(95%CI)*
All complications Females;OR = 2.26(1.48–3.47)
Metabolic syndrome (WHO criteria);OR = 3.48(2.26–5.37)
Metabolic syndrome (IDF criteria);OR = 2.28(1.84–4.90)
Coronary Metabolic syndrome (WHO criteria);OR = 3.10(1.48–6.49)
Metabolic syndrome (IDF criteria);OR = 1.96(1.15–4.89)
Cerebrovascular Females;OR = 2.46(1.06–5.37)
Metabolic syndrome (NCEP criteria);OR = 2.59(1.26–5.27)
Peripheral vascular Females; OR = 3.61(1.72–7.55)
Metabolic syndrome (WHO criteria);OR = 2.26(1.11–4.61)
Metabolic syndrome (NCEP criteria);OR = 2.74(1.82–5.33)
Retinopathy Metabolic syndrome (NCEP criteria);OR = 2.80(1.07–7.34)
Metabolic syndrome (IDF criteria);OR = 3.63(2.27–7.94)
Nephropathy Females; OR = 2.97(1.32–6.66)
Metabolic syndrome (WHO criteria); OR = 11.78(4.91–28.3)
Metabolic syndrome (IDF criteria);OR = 3.51(2.07–12.2)
Neuropathy Metabolic syndrome (NCEP criteria);OR = 12.41(1.44–106.9)
* For each component are indicated those components included in the regression equation. The rest of the components did not reach statistical 
significance and, as such, have not been included in the tableBMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
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representing a problem of health at the developed coun-
tries.
After adjusting for age and gender, the analyses performed
suggest that MS by WHO and IDF criteria are better predic-
tive of cardiovascular disease events (as independent fac-
tor) than those of the NCEP (as well the complications are
considered globally as well as individually). Individually,
WHO criteria predicts better coronary artery disease, vas-
cular disease and nephropathy; NCEP criteria the stroke,
arteriopathy, nephropathy and neuropathy; and finally
the IDF set predict globally complications, as well as cor-
onary, retinopathy and nephropathy.
Of note is that there is a high prevalence of type 2 diabetes
and of pre-diabetes in our sample. This is because a glu-
cose tolerance test was performed in all study subjects
(except those with known diabetes); the objective being to
discount previously-unidentified alterations of carbohy-
drate metabolism. This criterion provides added value to
the study since the prevalence identified is closer to the
reality. The total of diabetes and pre-diabetes was > 50%
of the study sample and which is of considerable note for
the future disease development.
The principal difficulty in the diagnosis of MS is the crite-
ria used. We followed the criteria of the NCEP-ATPIII
which are more clinically-based than those of the previous
WHO criteria of 1998. However, we performed the calcu-
lation based on the latest methodology as well. We did
not apply other diagnostic methods such as those of the
EGIR nor the AACE because the recommended tests were
tests are required laboratory facilities that are beyond our
reach (and that of most PC centers) such as analyses dem-
onstrating insulin resistance.
The concordance between the WHO and NCEP criteria
(kappa index of 0.66) and between the NCEP and IDF cri-
teria (kappa index of 0.87) provides weight to our proce-
dures and indicates that, in usual-care clinical practice it is
Cardiovascular disease (CVD) events segregated with respect to number of components of metabolic syndrome (MS); NCEP  criteria Figure 2
Cardiovascular disease (CVD) events segregated with respect to number of components of metabolic syn-















































0 1  2 3 4 5 
n=154 n=193 n=163 n=124 n=58 n=28BMC Public Health 2008, 8:251 http://www.biomedcentral.com/1471-2458/8/251
Page 9 of 12
(page number not for citation purposes)
not important which set of criteria are used to assess MS
but more importantly to be aware of MS and to detect its
components.
With respect rest to other methodological aspects, primary
health care provision is distributed according to the risk
factor status of the individual. The first clinical consulta-
tion would detect some aspects such as obesity and hyper-
tension and which require prompt action (confirmation
of diagnosis, dietary advice, life-style modifications) all of
which are standard in our type of clinical practice. In the
present study the added benefit for our general popula-
tion (and of other similar populations) is that of screen-
ing. We were able to detect pathologies which we were not
aware of (e.g. identification of subject with hyperglycemia
or hypertension) and to detect previously-unknown risk
factors for CVD. Further, we were able to provide advice
on life-style modifications, such as anti-smoking, diets,
exercise and body-weight control for what is an ostensibly
healthy population.
Further, the identification of patients with MS creates an
overall "attitude" for the individual in question such that
the idea is developed that the preoccupation should not
be towards only certain risk factors but, more importantly,
all components that have an impact of future CVD.
However, we need to reiterate that we did not conduct an
intervention study. Indeed, the measures we employed are
standard in PC practice.
The association of MS with cardiovascular disease
observed in the present study (OR = 2.56) is comparable
with an epidemiological study conducted in the USA
using a questionnaire on health (NHANES III) and in
which an odds ratio of 2 was calculated not only for myo-
Cardiovascular disease (CVD) events segregated with respect to number of components of metabolic syndrome (MS): WHO  criteria; * = alterations in glucose metabolism not included in the components Figure 3
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cardial infarction but also for cerebrovascular disease
(stroke) in both genders, and independently of age and
ethnicity [33].
The prevalence in the USA now is slighty higher compar-
ing data with newest NHANES from 1999–2000, increas-
ing up to 27.0% [34]. Considering all the criteria set
available nowadays, all of them are capable to predict car-
diovascular disease, in differents degrees [35]. For exam-
ple, stroke was predicted, in a 14-year follow-up in
Finland, better by WHO and NCEP set than other criteria
used [36].
The global prevalences in another European studies are
closer: in Italy, finding a 16.2% but in youngest popula-
tion [37]; in Greece in a nationwide survey, reaching a
23.6% [38] and in Great Britain finding a 29.8% (in
women, with highest mean age) [39]. In Germany was
lowest by NCEP definition (19.8%) but highest using the
IDF definition (32.7%) [40].
So, the prevalence is increasing with each newly published
definition of the MS and clearly associated with age and
gender, as these studies shows.
Figure 2 shows that the CVD complications had been
more numerous in the sub-group of subjects who had 3
components of MS, compared to those who had 4 or 5.
This can be explained by the small numbers of complica-
tions in the sub-groups. Figure 3 shows that the patients
who fulfilled 5 criteria on the WHO scale (the maximum)
had a rate of events that was almost triple that of other
sub-groups. The explanation in this case is that, apart from
being relatively few in absolute numbers, the WHO crite-
ria requires microalbuminuria as part of the MS diagnosis,
and which is a known independent risk factor for cardio-
vascular disease. Figure 4 shows CVD complications sim-
ilar to the Figure 2.
We believe, as well, that the better predictor of cardiovas-
cular disease achieved by the WHO criteria over those of
Cardiovascular disease (CVD) events segregated with respect to number of components of metabolic syndrome (MS); IDF cri- teria Figure 4
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the NCEP (Table 2) needs to take microalbuminuria into
account. The WHO criteria achieve a better prediction in
overall CVD events (coronary, nephropathy). Conversely,
the NCEP criteria is associated with a better prediction of
stroke and arteriopathy. And finally, IDF criteria is a good
predictor of retinopathy, nephropathy, coronary disease
and all events globally. With respect to concordance
between criteria used (kappa index of 0.66 between WHO
and NCEP; and 0.87 between NCEP and IDF) we propose
that the clinical effort should be applied to identifying the
patients with high risk, irrespective of the choice of criteria
used.
Undoubtedly, age and diabetes per se adds an important
cardiovascular disease risk in all cases. Indeed, we need to
highlight that in this sub-group, the MS modulates the
risk such that those diabetic subjects with MS suffer more
complications (63.9% vs. 46.6%) than those diabetic sub-
jects without MS. Conversely, in the sub-analyses which
excluded the patients with diabetes, and not taking the
presence of diabetes into the definition of MS, the predic-
tion of cardiovascular disease events was greater globally
when MS was present (17.2% vs. 8.9%).
Conclusion
In conclusion, we believe that MS diagnosis is simple and
easy clinical tool to assess potential cardiovascular risk
and, as such, can identify those patients who can benefit
most from the prioritization of health-care resources, and
we conclude that MS and concomitant CVD risk is high in
ostensibly normal population attending primary care
clinics.
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